News >

DS-1062 Elicits Intriguing Early-Phase Data in Advanced NSCLC

Gina Columbus @ginacolumbusonc
Published: Thursday, Sep 12, 2019

Rebecca S. Heist, MD, MPH, medical oncologist, Massachusetts General Hospital Cancer Center

Rebecca S. Heist, MD, MPH

The investigational Trop-2–targeting antibody-drug conjugate (ADC) DS-1062 demonstrated antitumor activity in unselected patients with unresectable, advanced non–small cell lung cancer (NSCLC) who are refractory to or relapsed following standard therapy or for whom no standard treatment is available, according to updated phase I findings presented at the 2019 World Conference on Lung Cancer.1,2
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication